TrianglePembrolizumab (NCT07740941)
Pembrolizumab trial for Melanoma (Skin Cancer) (NCT07740941). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with removable stage IIIB through M1a melanoma of the skin or an unknown primary site.
The idea: compare two pembrolizumab infusions with ipilimumab plus nivolumab followed by nivolumab alone. The infusions are three weeks apart, followed by lymph-node surgery. These antibodies block PD-1 or CTLA-4 immune brakes. Neither group receives planned postoperative drug treatment, regardless of the tumor's response. Researchers track survival to assess this approach.
This phase 2 study plans 55 patients. Stergios Moschos leads the recruiting UNC Lineberger site in Chapel Hill.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.